We report net peptide content, not just purity — so the milligrams you dose aren't padded with water and counter-ion. RP-HPLC purity and ESI-MS identity, on a lot-numbered COA.
Net peptide content, not just purity — RP-HPLC + ESI-MS, lot-numbered COA.
Net peptide content on every lot's COA.
Reading a Peptide HPLC Trace — A 5-Minute Field Guide for Bench Scientists. Read our briefing →
Reading a peptide HPLC trace — a field guide. Read →
On reading HPLC traces. Read →
ActRIIB-Fc decoy receptor fusion protein · myostatin pathway
Lyochem primary owner
This Lyochem page is the primary SEO owner for research labs, CROs, and method-development teams qualifying ACE-031 (ActRIIB-Fc Fusion) as a documented research-standard lot. The page should answer whether the buyer can review HPLC purity, identity confirmation, lot continuity, stability handling, and assay-fit documentation before ordering.
Overview
ACE-031 acts as a soluble ligand trap: human Activin Receptor Type IIB (ActRIIB), reduced to its extracellular ligand-binding region, is fused to a human IgG1 Fc, and the resulting fusion sequesters myostatin, activin A, and related TGF-β superfamily ligands before they can engage membrane-bound ActRIIB on muscle and other tissues. Removing myostatin's tonic restraint on skeletal-muscle growth drives increased muscle mass — the rationale behind the molecule's clinical program in Duchenne muscular dystrophy and other wasting conditions, a program halted in Phase 2 owing to off-target effects. Structurally it is a recombinant, glycosylated receptor-Fc chimera rather than a synthetic peptide. Lyochem supplies ACE-031 as a lyophilized reference standard — a recombinant fusion protein — at ≥99.0% HPLC. Its glycoprotein nature dictates a biologics-style release panel: RP-HPLC for chemical purity, reducing and non-reducing SDS-PAGE to resolve size and disulfide arrangement, LC-MS/MS peptide mapping for sequence coverage, glycan profiling across the ActRIIB-ECD and Fc portions, and a myostatin-binding bioactivity assay. The 1 mg fill aligns with typical aliquot volumes for receptor-pharmacology work.
Applications & buyer fit
Other research peptides in this category — Melanotan-1, Melanotan-2, PT-141, ACE-031, Adipotide-FTTP, EPO, HCG, HMG — ship to research labs studying topics outside the GH / cognitive / immune / mitochondrial / repair / longevity / Khavinson clusters. Each peptide has its own analytical-packet emphasis (e.g. glycoprotein bioassay in IU/mg for HCG; cyclised-form confirmation for oxytocin) noted in the per-product CoA scope.
Academic Laboratories
Universities, medical schools, and government research institutes qualifying a reference standard for a method-development or in vivo workflow.
Every release ships with its own batch-specific CoA — identity, purity, and the analytical scope agreed at quote stage, tied to the exact lot you receive.
Review a representative batch CoA before you order, so you can confirm the packet matches what your method or sponsor audit needs.
Supplied strictly as a research reagent to research institutions — not a finished dosage form and not for human administration. Buyer qualification runs at the inquiry stage.
Specifications
Documentation available on request
Regulatory note
A recombinant fusion protein with no single registered CAS on record. Per-batch COA data should be used to verify identity, the glycosylation profile, and the expression system. Offered for research use only.
Selected literature
Frequently asked questions
A recombinant ActRIIB-Fc construct is characterized by a panel rather than a single test. SDS-PAGE under reducing and non-reducing conditions reports apparent molecular weight and confirms the disulfide-linked dimer versus monomer, flagging clipping or aggregation. Intact-mass LC-MS establishes the deconvoluted mass including expected glycosylation heterogeneity, while size-exclusion chromatography quantifies monomer content and any high-molecular-weight species. For sequence-level confirmation, tryptic-digest peptide mapping by LC-MS/MS verifies the ActRIIB extracellular-domain and Fc regions. Together these establish that the delivered protein matches the intended fusion design before it enters binding studies.
At the 10-1000 nM range, surface adsorption is the main threat to accurate results, so reconstitute and dilute in cell-culture-grade buffer containing a carrier such as 0.1% BSA to limit loss to vessel walls. Minimize freeze-thaw stress by aliquoting the reconstituted protein for single use and holding aliquots cold, since repeated cycling promotes the aggregation that SEC would later detect. Before a critical binding run, it is prudent to re-confirm monomer integrity, because a decoy-receptor protein that has partially aggregated will report a misleadingly low active concentration against myostatin and related ligands.
Related peptides